 Paula Riggs
Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Substance-Related Disorders | 38 | 2024 | 1080 | 4.870 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 18 | 2015 | 426 | 1.800 |
Why?
| | Marijuana Smoking | 5 | 2023 | 254 | 1.490 |
Why?
| | Central Nervous System Stimulants | 9 | 2013 | 175 | 1.320 |
Why?
| | Prescription Drug Misuse | 3 | 2019 | 47 | 1.110 |
Why?
| | Cannabis | 4 | 2023 | 497 | 1.100 |
Why?
| | Prescription Drugs | 2 | 2019 | 115 | 0.990 |
Why?
| | Fluoxetine | 3 | 2019 | 55 | 0.980 |
Why?
| | Conduct Disorder | 6 | 2012 | 187 | 0.880 |
Why?
| | Substance Abuse, Intravenous | 2 | 2016 | 117 | 0.830 |
Why?
| | Adolescent Behavior | 7 | 2016 | 530 | 0.830 |
Why?
| | Adolescent | 48 | 2024 | 21503 | 0.830 |
Why?
| | Mental Disorders | 7 | 2025 | 1091 | 0.760 |
Why?
| | Opioid-Related Disorders | 3 | 2019 | 535 | 0.720 |
Why?
| | Escherichia coli | 10 | 2021 | 827 | 0.710 |
Why?
| | Problem Behavior | 1 | 2022 | 103 | 0.700 |
Why?
| | Hallucinogens | 1 | 2023 | 107 | 0.680 |
Why?
| | Methylphenidate | 6 | 2012 | 42 | 0.660 |
Why?
| | Recombinant Fusion Proteins | 9 | 2021 | 662 | 0.640 |
Why?
| | Maltose-Binding Proteins | 7 | 2021 | 13 | 0.640 |
Why?
| | Psychiatry | 1 | 2022 | 184 | 0.630 |
Why?
| | Escherichia coli Proteins | 8 | 2021 | 200 | 0.620 |
Why?
| | School Health Services | 2 | 2016 | 226 | 0.490 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2019 | 281 | 0.480 |
Why?
| | Health Care Reform | 1 | 2016 | 105 | 0.470 |
Why?
| | Acetic Acid | 1 | 2015 | 22 | 0.470 |
Why?
| | Honey | 1 | 2015 | 11 | 0.470 |
Why?
| | Early Medical Intervention | 1 | 2016 | 58 | 0.470 |
Why?
| | Depression | 2 | 2019 | 1464 | 0.450 |
Why?
| | Homeless Youth | 1 | 2013 | 17 | 0.420 |
Why?
| | Academies and Institutes | 1 | 2013 | 54 | 0.410 |
Why?
| | Carrier Proteins | 6 | 2001 | 737 | 0.410 |
Why?
| | Depressive Disorder, Major | 4 | 2011 | 374 | 0.410 |
Why?
| | Mental Health | 3 | 2025 | 735 | 0.400 |
Why?
| | Public Health | 2 | 2016 | 582 | 0.400 |
Why?
| | Awards and Prizes | 1 | 2013 | 72 | 0.390 |
Why?
| | Humans | 56 | 2025 | 138201 | 0.390 |
Why?
| | Depressive Disorder | 4 | 2002 | 389 | 0.370 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 740 | 0.370 |
Why?
| | Drug Overdose | 1 | 2016 | 354 | 0.370 |
Why?
| | Analgesics, Opioid | 2 | 2019 | 1049 | 0.360 |
Why?
| | Pemoline | 2 | 2004 | 4 | 0.350 |
Why?
| | Periodicals as Topic | 1 | 2013 | 211 | 0.350 |
Why?
| | Empirical Research | 1 | 2010 | 22 | 0.330 |
Why?
| | Research Subjects | 1 | 2010 | 43 | 0.320 |
Why?
| | Mutant Proteins | 1 | 2010 | 103 | 0.320 |
Why?
| | Psychology, Adolescent | 2 | 2007 | 68 | 0.300 |
Why?
| | Diagnosis, Dual (Psychiatry) | 6 | 2015 | 39 | 0.280 |
Why?
| | Mutation, Missense | 1 | 2010 | 341 | 0.280 |
Why?
| | Neurobiology | 1 | 2007 | 14 | 0.280 |
Why?
| | Education, Continuing | 1 | 2008 | 40 | 0.280 |
Why?
| | Comorbidity | 9 | 2016 | 1645 | 0.270 |
Why?
| | Drug Therapy | 1 | 2008 | 84 | 0.270 |
Why?
| | Schizophrenia | 2 | 2025 | 450 | 0.250 |
Why?
| | Family | 5 | 2022 | 676 | 0.240 |
Why?
| | Drug Prescriptions | 1 | 2008 | 257 | 0.240 |
Why?
| | Protein Engineering | 2 | 2010 | 107 | 0.230 |
Why?
| | Personality Disorders | 3 | 2006 | 72 | 0.230 |
Why?
| | Juvenile Delinquency | 4 | 2004 | 104 | 0.230 |
Why?
| | Protein Disulfide-Isomerases | 3 | 2015 | 11 | 0.220 |
Why?
| | Research | 1 | 2007 | 450 | 0.220 |
Why?
| | Linear Models | 2 | 2018 | 851 | 0.210 |
Why?
| | Male | 31 | 2021 | 68035 | 0.210 |
Why?
| | Medical Marijuana | 1 | 2025 | 123 | 0.200 |
Why?
| | Combined Modality Therapy | 6 | 2011 | 1238 | 0.200 |
Why?
| | Tobacco Use Disorder | 3 | 2011 | 244 | 0.200 |
Why?
| | Protein Folding | 3 | 2015 | 279 | 0.200 |
Why?
| | Dronabinol | 1 | 2025 | 233 | 0.190 |
Why?
| | Adolescent Health | 1 | 2022 | 39 | 0.190 |
Why?
| | Oxidoreductases | 2 | 2015 | 96 | 0.190 |
Why?
| | Young Adult | 6 | 2019 | 13298 | 0.180 |
Why?
| | Patient Care Planning | 1 | 2002 | 150 | 0.180 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2021 | 847 | 0.170 |
Why?
| | Mental Health Services | 1 | 2005 | 433 | 0.170 |
Why?
| | Child | 7 | 2023 | 21862 | 0.160 |
Why?
| | Genetic Vectors | 6 | 2001 | 335 | 0.160 |
Why?
| | Female | 21 | 2017 | 73713 | 0.160 |
Why?
| | Prokaryotic Cells | 1 | 2019 | 5 | 0.160 |
Why?
| | Adult | 13 | 2021 | 38190 | 0.150 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2008 | 1367 | 0.150 |
Why?
| | Oxidation-Reduction | 3 | 2019 | 1075 | 0.150 |
Why?
| | Epitopes | 1 | 2021 | 476 | 0.150 |
Why?
| | Sex Factors | 5 | 2017 | 2055 | 0.150 |
Why?
| | Prescriptions | 1 | 2019 | 71 | 0.150 |
Why?
| | Treatment Outcome | 6 | 2016 | 10914 | 0.150 |
Why?
| | Practice Patterns, Physicians' | 1 | 2008 | 1305 | 0.150 |
Why?
| | Bupropion | 1 | 1998 | 47 | 0.150 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 1998 | 59 | 0.150 |
Why?
| | Longitudinal Studies | 2 | 2023 | 2837 | 0.140 |
Why?
| | Disulfides | 3 | 2015 | 98 | 0.140 |
Why?
| | Deoxyribonucleases, Type II Site-Specific | 1 | 1997 | 14 | 0.140 |
Why?
| | Green Fluorescent Proteins | 1 | 2019 | 398 | 0.140 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 1998 | 61 | 0.140 |
Why?
| | Cytoplasm | 2 | 2015 | 269 | 0.130 |
Why?
| | Motivational Interviewing | 1 | 2019 | 115 | 0.130 |
Why?
| | Antisocial Personality Disorder | 1 | 1998 | 152 | 0.130 |
Why?
| | Clonidine | 1 | 1996 | 34 | 0.130 |
Why?
| | Molecular Sequence Data | 6 | 2010 | 2925 | 0.120 |
Why?
| | Genes, Reporter | 1 | 1997 | 272 | 0.120 |
Why?
| | Chromatography, Affinity | 4 | 2001 | 86 | 0.120 |
Why?
| | Solubility | 2 | 2010 | 241 | 0.120 |
Why?
| | Bayes Theorem | 1 | 2018 | 411 | 0.120 |
Why?
| | Organisms, Genetically Modified | 1 | 2015 | 15 | 0.120 |
Why?
| | Sulfenic Acids | 1 | 2015 | 7 | 0.120 |
Why?
| | Statistical Distributions | 1 | 2015 | 8 | 0.120 |
Why?
| | Chromatography, Ion Exchange | 3 | 2001 | 53 | 0.120 |
Why?
| | Problem Solving | 2 | 2006 | 155 | 0.120 |
Why?
| | Social Behavior Disorders | 1 | 1995 | 15 | 0.110 |
Why?
| | Psychotropic Drugs | 1 | 1995 | 73 | 0.110 |
Why?
| | Antidepressive Agents | 1 | 1997 | 245 | 0.110 |
Why?
| | Placebos | 2 | 2011 | 197 | 0.110 |
Why?
| | Behavior, Addictive | 1 | 2015 | 88 | 0.110 |
Why?
| | Antibody Formation | 1 | 2015 | 299 | 0.110 |
Why?
| | Risk | 1 | 2016 | 908 | 0.100 |
Why?
| | Delayed-Action Preparations | 2 | 2011 | 177 | 0.100 |
Why?
| | Cloning, Molecular | 5 | 2000 | 535 | 0.100 |
Why?
| | Risk Factors | 2 | 2023 | 10366 | 0.100 |
Why?
| | Interpersonal Relations | 2 | 2006 | 409 | 0.100 |
Why?
| | Smoking | 3 | 2011 | 1601 | 0.100 |
Why?
| | Models, Molecular | 3 | 2010 | 1598 | 0.090 |
Why?
| | Colorado | 4 | 2017 | 4526 | 0.090 |
Why?
| | Crystallography, X-Ray | 3 | 2021 | 481 | 0.090 |
Why?
| | Models, Statistical | 1 | 2015 | 667 | 0.090 |
Why?
| | Immunoglobulin G | 1 | 2015 | 903 | 0.090 |
Why?
| | Protein Structure, Tertiary | 2 | 2010 | 863 | 0.090 |
Why?
| | Behavior Therapy | 3 | 2015 | 268 | 0.090 |
Why?
| | DNA | 1 | 1997 | 1448 | 0.080 |
Why?
| | Statistics, Nonparametric | 2 | 2004 | 430 | 0.080 |
Why?
| | Propylamines | 1 | 2010 | 11 | 0.080 |
Why?
| | Periplasmic Proteins | 1 | 2009 | 4 | 0.080 |
Why?
| | Bacteroides fragilis | 1 | 2009 | 12 | 0.080 |
Why?
| | Alcoholic Beverages | 1 | 2010 | 30 | 0.080 |
Why?
| | Polysaccharides | 1 | 2010 | 86 | 0.080 |
Why?
| | Psychiatric Status Rating Scales | 4 | 2011 | 558 | 0.080 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 309 | 0.080 |
Why?
| | Protein Structure, Secondary | 1 | 2010 | 373 | 0.080 |
Why?
| | Alcohol-Related Disorders | 2 | 2011 | 122 | 0.070 |
Why?
| | Epidemiologic Studies | 1 | 2008 | 71 | 0.070 |
Why?
| | Harm Reduction | 1 | 2007 | 39 | 0.070 |
Why?
| | Plasmids | 4 | 2015 | 359 | 0.070 |
Why?
| | Base Sequence | 4 | 2000 | 2180 | 0.070 |
Why?
| | Amino Acid Sequence | 2 | 2010 | 2159 | 0.070 |
Why?
| | Education, Medical, Continuing | 1 | 2008 | 129 | 0.060 |
Why?
| | Kinetics | 1 | 2010 | 1641 | 0.060 |
Why?
| | Citalopram | 1 | 2006 | 35 | 0.060 |
Why?
| | Adaptation, Psychological | 1 | 2011 | 672 | 0.060 |
Why?
| | Health Surveys | 1 | 2008 | 521 | 0.060 |
Why?
| | Marijuana Abuse | 2 | 2005 | 226 | 0.060 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 253 | 0.060 |
Why?
| | Patient Selection | 1 | 2009 | 692 | 0.060 |
Why?
| | Managed Care Programs | 1 | 2005 | 138 | 0.060 |
Why?
| | Mutation | 2 | 2015 | 3993 | 0.060 |
Why?
| | Pilot Projects | 2 | 2000 | 1743 | 0.050 |
Why?
| | Age of Onset | 1 | 2005 | 519 | 0.050 |
Why?
| | Alcohol Drinking | 2 | 2015 | 819 | 0.050 |
Why?
| | Motivation | 2 | 2010 | 585 | 0.050 |
Why?
| | Narcotics | 1 | 2003 | 54 | 0.050 |
Why?
| | Aged | 2 | 2016 | 24134 | 0.050 |
Why?
| | Patient Education as Topic | 1 | 2008 | 763 | 0.050 |
Why?
| | Research Design | 3 | 2018 | 1117 | 0.050 |
Why?
| | Middle Aged | 3 | 2016 | 33711 | 0.050 |
Why?
| | Child Behavior | 1 | 2004 | 245 | 0.050 |
Why?
| | Recombinant Proteins | 3 | 2012 | 1354 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2012 | 2857 | 0.050 |
Why?
| | Osmosis | 2 | 2012 | 14 | 0.050 |
Why?
| | Safety | 1 | 2004 | 345 | 0.050 |
Why?
| | Alkaline Phosphatase | 2 | 2015 | 151 | 0.050 |
Why?
| | Child, Preschool | 1 | 1996 | 11115 | 0.040 |
Why?
| | Periplasmic Binding Proteins | 1 | 2001 | 13 | 0.040 |
Why?
| | Narcotic Antagonists | 1 | 2003 | 184 | 0.040 |
Why?
| | Periplasm | 1 | 2001 | 13 | 0.040 |
Why?
| | Health Promotion | 1 | 2007 | 745 | 0.040 |
Why?
| | Drug Compounding | 1 | 2021 | 101 | 0.040 |
Why?
| | Enteropeptidase | 1 | 2000 | 2 | 0.040 |
Why?
| | Amylose | 1 | 2000 | 4 | 0.040 |
Why?
| | Maltose | 1 | 2000 | 8 | 0.040 |
Why?
| | Factor Xa | 1 | 2000 | 32 | 0.040 |
Why?
| | Protein Denaturation | 1 | 2000 | 74 | 0.040 |
Why?
| | Durapatite | 1 | 2000 | 36 | 0.040 |
Why?
| | Administration, Oral | 2 | 2012 | 788 | 0.040 |
Why?
| | Molecular Imaging | 1 | 2019 | 57 | 0.040 |
Why?
| | Personality Assessment | 2 | 1997 | 83 | 0.040 |
Why?
| | Genetic Engineering | 1 | 2019 | 93 | 0.040 |
Why?
| | Parent-Child Relations | 3 | 2006 | 279 | 0.040 |
Why?
| | Genes, Bacterial | 2 | 1989 | 166 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2021 | 550 | 0.040 |
Why?
| | Monosaccharide Transport Proteins | 2 | 1988 | 51 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2001 | 463 | 0.040 |
Why?
| | Referral and Consultation | 2 | 2009 | 796 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2000 | 442 | 0.040 |
Why?
| | ATP-Binding Cassette Transporters | 2 | 1988 | 120 | 0.030 |
Why?
| | Cohort Studies | 2 | 2005 | 5717 | 0.030 |
Why?
| | Hydrogen Peroxide | 1 | 2019 | 332 | 0.030 |
Why?
| | Likelihood Functions | 1 | 2018 | 143 | 0.030 |
Why?
| | Biosensing Techniques | 1 | 2019 | 134 | 0.030 |
Why?
| | Magnesium | 1 | 1997 | 157 | 0.030 |
Why?
| | DNA, Recombinant | 1 | 1997 | 48 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2005 | 1124 | 0.030 |
Why?
| | Substrate Specificity | 1 | 1997 | 384 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1997 | 373 | 0.030 |
Why?
| | Catalysis | 1 | 1997 | 317 | 0.030 |
Why?
| | Child Behavior Disorders | 1 | 1997 | 142 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2008 | 7683 | 0.030 |
Why?
| | Prevalence | 2 | 2017 | 2744 | 0.030 |
Why?
| | Ribonuclease, Pancreatic | 1 | 2015 | 12 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2003 | 1545 | 0.030 |
Why?
| | Surface Plasmon Resonance | 1 | 2015 | 88 | 0.030 |
Why?
| | Glycosylation | 1 | 2015 | 161 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2015 | 339 | 0.030 |
Why?
| | Psychotherapy | 2 | 2006 | 179 | 0.030 |
Why?
| | Personality Inventory | 1 | 1995 | 141 | 0.030 |
Why?
| | Stochastic Processes | 1 | 2015 | 70 | 0.030 |
Why?
| | Algorithms | 1 | 2002 | 1709 | 0.030 |
Why?
| | Copper | 1 | 2015 | 110 | 0.030 |
Why?
| | Recurrence | 1 | 1998 | 1102 | 0.030 |
Why?
| | Protein Conformation | 1 | 1997 | 944 | 0.030 |
Why?
| | Substance Abuse Treatment Centers | 2 | 2009 | 47 | 0.030 |
Why?
| | Bacteriophages | 1 | 2015 | 99 | 0.030 |
Why?
| | Protein Transport | 1 | 2015 | 440 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 989 | 0.030 |
Why?
| | Antibodies | 1 | 2015 | 406 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 851 | 0.020 |
Why?
| | Alcoholism | 1 | 2000 | 819 | 0.020 |
Why?
| | Blotting, Western | 1 | 2015 | 1224 | 0.020 |
Why?
| | Bacterial Proteins | 2 | 1989 | 897 | 0.020 |
Why?
| | Patient Care Team | 1 | 1998 | 636 | 0.020 |
Why?
| | Mandatory Programs | 1 | 2012 | 17 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2019 | 1319 | 0.020 |
Why?
| | HIV Infections | 1 | 2007 | 2943 | 0.020 |
Why?
| | Genetic Testing | 1 | 2015 | 457 | 0.020 |
Why?
| | Membrane Proteins | 2 | 1989 | 1152 | 0.020 |
Why?
| | Thioredoxins | 1 | 2012 | 31 | 0.020 |
Why?
| | Ethanol | 1 | 1997 | 618 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 1996 | 678 | 0.020 |
Why?
| | Risk-Taking | 1 | 2015 | 345 | 0.020 |
Why?
| | Patient Compliance | 1 | 1996 | 596 | 0.020 |
Why?
| | Amino Acids | 1 | 2015 | 499 | 0.020 |
Why?
| | Age Factors | 1 | 1999 | 3262 | 0.020 |
Why?
| | Atomoxetine Hydrochloride | 1 | 2010 | 8 | 0.020 |
Why?
| | Adrenergic Uptake Inhibitors | 1 | 2010 | 18 | 0.020 |
Why?
| | United States | 1 | 2008 | 14983 | 0.020 |
Why?
| | Interview, Psychological | 1 | 2010 | 95 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 2009 | 66 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2010 | 237 | 0.020 |
Why?
| | Checklist | 1 | 2010 | 98 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2012 | 357 | 0.020 |
Why?
| | Community Mental Health Centers | 1 | 2009 | 13 | 0.020 |
Why?
| | Temperature | 1 | 2012 | 664 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 1995 | 1458 | 0.020 |
Why?
| | Gene Deletion | 1 | 2009 | 390 | 0.020 |
Why?
| | Social Work | 1 | 2009 | 86 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2009 | 307 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2010 | 1936 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 1032 | 0.010 |
Why?
| | Age Distribution | 1 | 2004 | 397 | 0.010 |
Why?
| | Sex Distribution | 1 | 2004 | 380 | 0.010 |
Why?
| | Smoking Prevention | 1 | 2004 | 182 | 0.010 |
Why?
| | Disease Progression | 1 | 2011 | 2734 | 0.010 |
Why?
| | Counseling | 1 | 2006 | 390 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2007 | 574 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 1479 | 0.010 |
Why?
| | Models, Biological | 1 | 2009 | 1785 | 0.010 |
Why?
| | Sampling Studies | 1 | 1996 | 101 | 0.010 |
Why?
| | Wechsler Scales | 1 | 1996 | 55 | 0.010 |
Why?
| | RNA Probes | 1 | 1995 | 13 | 0.010 |
Why?
| | Intelligence | 1 | 1996 | 129 | 0.010 |
Why?
| | Blotting, Southern | 1 | 1995 | 75 | 0.010 |
Why?
| | Mood Disorders | 1 | 1996 | 134 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 1996 | 524 | 0.010 |
Why?
| | Aggression | 1 | 1996 | 199 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 6848 | 0.010 |
Why?
| | Genotype | 2 | 1989 | 1873 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1996 | 1314 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2004 | 5860 | 0.010 |
Why?
| | Incidence | 1 | 1997 | 2820 | 0.010 |
Why?
| | Transformation, Bacterial | 1 | 1989 | 8 | 0.000 |
Why?
| | SEC Translocation Channels | 1 | 1989 | 10 | 0.000 |
Why?
| | Restriction Mapping | 1 | 1989 | 75 | 0.000 |
Why?
| | Lac Operon | 1 | 1989 | 44 | 0.000 |
Why?
| | DNA Restriction Enzymes | 1 | 1988 | 51 | 0.000 |
Why?
| | Genes | 1 | 1988 | 229 | 0.000 |
Why?
| | Cross-Sectional Studies | 1 | 1997 | 5518 | 0.000 |
Why?
|
|
Riggs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|